Retatrutide met the primary endpoints for obesity at 80 weeks, delivering clinically meaningful weight loss in both trials. In TRIUMPH-2, retatrutide resulted in 12.7%, 19.1% and 20.8% weight loss (vs 4.0% with placebo; efficacy estimand) and 1.4%, 1.6% and 1.5% reductions in HbA1c (vs 0.2% with placebo) from 7.7% at baseline, at the 4 mg, 9 mg, and 12 mg doses, respectively, in participants with obesity and type 2 diabetes. In TRIUMPH-3 with participants severe obesity and cardiovascular disease (+/- type 2 diabetes), weight loss reached 21.6% (9 mg) and 22.6% (12 mg; vs 3.2% with placebo). In both placebo and retatrutide arms, major adverse cardiovascular events (MACE) occurred less frequently than anticipated, and retatrutide meaningfully reduced certain cardiovascular risk factors.